|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
70,932,000 |
Market
Cap: |
2.68(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$15.81 - $52.44 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on changing the paradigm for the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and hyperphagia, a pathological and insatiable hunger. Co. is developing IMCIVREE (setmelanotide) as a medicine strategy for a subset of individuals who have severe obesity due to genetic variants that impair the melanocortin-4 receptor pathway, a pathway in the brain that is responsible for regulating hunger, caloric intake and energy expenditure, which consequently affect body weight.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
164,376 |
307,851 |
390,685 |
429,469 |
Total Sell Value |
$6,457,019 |
$13,147,582 |
$15,609,906 |
$16,448,857 |
Total People Sold |
7 |
7 |
7 |
8 |
Total Sell Transactions |
10 |
32 |
42 |
61 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gottesdiener Keith Michael |
CEO and President |
|
2019-02-27 |
4 |
AS |
$30.01 |
$54,438 |
D/D |
(1,814) |
525,617 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2019-02-26 |
4 |
AS |
$30.13 |
$19,133 |
D/D |
(635) |
527,431 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2019-02-19 |
4 |
AS |
$30.05 |
$27,586 |
D/D |
(918) |
528,066 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2019-02-15 |
4 |
AS |
$30.02 |
$360,300 |
D/D |
(12,002) |
528,984 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2019-02-13 |
4 |
AS |
$30.00 |
$118,020 |
D/D |
(3,934) |
540,986 |
|
- |
|
Smith Hunter C |
Chief Financial Officer |
|
2019-01-31 |
4 |
OE |
$6.88 |
$20,640 |
D/D |
3,000 |
6,000 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2019-01-23 |
4 |
AS |
$30.21 |
$3,172 |
D/D |
(105) |
544,920 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2019-01-22 |
4 |
AS |
$30.05 |
$471,004 |
D/D |
(15,674) |
545,025 |
|
- |
|
Gottesdiener Keith Michael |
CEO & President |
|
2019-01-18 |
4 |
AS |
$30.01 |
$303,551 |
D/D |
(10,115) |
560,699 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-01-16 |
4 |
AS |
$30.00 |
$6,000 |
D/D |
(200) |
42,339 |
|
- |
|
Gottesdiener Keith Michael |
CEO & President |
|
2019-01-16 |
4 |
AS |
$30.00 |
$19,860 |
D/D |
(662) |
570,814 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2018-12-03 |
4 |
AS |
$30.00 |
$16,890 |
D/D |
(563) |
571,476 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2018-11-02 |
4 |
AS |
$30.09 |
$1,143,420 |
D/D |
(38,000) |
42,539 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2018-11-02 |
4 |
OE |
$4.59 |
$174,238 |
D/D |
28,200 |
80,539 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2018-11-02 |
4 |
AS |
$30.08 |
$496,320 |
D/D |
(16,500) |
572,039 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2018-09-25 |
4 |
AS |
$27.45 |
$947,540 |
D/D |
(31,800) |
52,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2018-09-25 |
4 |
OE |
$4.59 |
$100,062 |
D/D |
21,800 |
84,139 |
|
- |
|
Smith Hunter C |
Chief Financial Officer |
|
2018-09-05 |
4 |
OE |
$6.88 |
$20,640 |
D/D |
3,000 |
3,000 |
|
- |
|
Levin Mark J |
10% Owner |
|
2018-08-30 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,000,000) |
2,981,437 |
|
- |
|
Desikan Nithya |
Chief Commercial Officer |
|
2018-08-10 |
4 |
OE |
$6.88 |
$99,994 |
D/D |
14,534 |
14,534 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2018-06-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
62,339 |
|
- |
|
Orbimed Capital Gp V Llc |
See Remarks |
|
2018-05-22 |
4 |
S |
$30.38 |
$595,768 |
I/I |
(19,580) |
2,750,079 |
|
- |
|
Orbimed Capital Gp V Llc |
10% Owner |
|
2018-05-21 |
4 |
S |
$31.01 |
$1,938,125 |
I/I |
(62,500) |
2,769,659 |
|
- |
|
Orbimed Capital Gp V Llc |
10% Owner |
|
2018-05-18 |
4 |
S |
$30.77 |
$2,127,315 |
I/I |
(69,136) |
2,832,159 |
|
- |
|
Gottesdiener Keith Michael |
C.E.O. and President |
|
2018-05-09 |
4 |
OE |
$4.59 |
$13,770 |
D/D |
3,000 |
588,539 |
|
- |
|
251 Records found
|
|
Page 9 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|